Point72 Asset Management
FBRX icon

Point72 Asset Management’s Forte Biosciences FBRX Stock Holding History

Point72 Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-487,275
Closed -$13.3M – 4004
2025
Q4 		$13.3M Buy
+487,275
New +$8.54M 0.01% 1171
2021
Q3 		– Sell
-26,738
Closed -$22.5M – 1101
2021
Q2 		$22.5M Buy
26,738
+6,730
+34% +$6.06M 0.1% 260
2021
Q1 		$17.1M Buy
20,008
+16,608
+488% +$13.6M 0.08% 296
2020
Q4 		$3.1M Buy
+3,400
New +$3.2M 0.02% 664

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Point72 Asset Management's FBRX Position: Q1 2026 in Review

Point72 Asset Management sold out of Forte Biosciences (FBRX) in Q1 2026, closing a stake of 487,275 shares — an estimated $13.3M sold.

Point72 Asset Management first reported a position in FBRX in Q4 2020 and held it in 4 quarters. The position peaked at $22.5M in Q2 2021. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Point72 Asset Management reported no remaining Forte Biosciences position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 487,275 Forte Biosciences shares in Q1 2026, an estimated $13.3M.
  • Point72 Asset Management first reported a position in Forte Biosciences in Q4 2020 and held it in 4 quarters.
  • Point72 Asset Management's Forte Biosciences position peaked at $22.5M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.